Mesoblast (MESO) Other financing activities (2017 - 2025)
Mesoblast (MESO) posted quarterly Other financing activities of -$3.9 million for Q4 2025, down 221.86% year-on-year from $3.2 million in Q4 2024, and down 221.86% on a QoQ basis from $3.2 million in Q4 2024.
Mesoblast (MESO) Other financing activities (2017 - 2025) Analysis & Trends
Mesoblast (MESO) has reported Other financing activities for 4 consecutive years, with -$3.9 million the latest figure, recorded in Q4 2025.
- Quarterly Other financing activities fell 221.86% year-over-year to -$3.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$3.9 million (down 221.86% YoY) and the FY2022 annual result came in at $8.1 million, down 37.69% from the prior year.
- Other financing activities slipped to -$3.9 million in Q4 2025 per MESO's latest filing, from $3.2 million in the prior quarter.
- Over the last five years, Other financing activities for MESO reached as high as $3.2 million in Q4 2024 and fell as low as -$3.9 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Mesoblast | 2.08 Bn | 1.95 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -3.89 Mn |
| Dec 31, 2025 | -3.89 Mn |
| Dec 31, 2024 | 3.19 Mn |
| Dec 31, 2024 | 3.19 Mn |
| Jun 30, 2018 | -409,000.00 |
| Jun 30, 2018 | -409,000.00 |
| Sep 30, 2017 | -543,000.00 |
| Sep 30, 2017 | -543,000.00 |